ESR1 and breast cancer: ERα and its cognate ligand oestrogen are the major drivers of tumour development and disease progression in luminal breast cancers, and agents that impair ER signalling in ER-positive breast cancers represent highly successful targeted therapies that are widely used in both early breast cancer, as well as the metastatic setting2.